ASCO GUIDELINES Bundle

Hereditary Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475464

Contents of this Issue

Navigation

Page 11 of 11

Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncology Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/breast-cancer-guidelines. Copyright ©2021 by American Society of Clinical Oncology. All rights reserved. Source Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline. J Clin Oncol. 2020 April 3 doi: 10.1200/JCO.20.00299 Tung NM, Somerfield MR, Boughey JC, et al. Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Guideline Recommendation Update. J Clin Oncol. 2021 August 3 doi: 10.1200/ JCO.21.01532 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2021 All rights reserved ASCOTUNG7212a ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/breast-cancer-guidelines. Abbreviations BCT, breast conserving therapy; CBC, contralateral breast cancer; CRRM, contralateral risk-reducing mastectomy; HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance imaging ; PARP, Poly (ADP-ribose) polymerase; TNBC, triple negative breast cancer Recommendation Grading Type Benefit/harm Evidence Quality Strength of Recommendation EB Evidence- based B Benefits outweigh harms H High Strong FC Formal consensus H Harms outweigh benefits I Intermediate Moderate IC Informal consensus B/H Relative balance of benefits and harms L Low Weak Ins Insufficient

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Hereditary Breast Cancer